Evidence map›Paper›PMID 34838105›Full record

ArticleTrials2021

The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial.

Julia Nordlund, Richard S Henry, Linda Kwakkenbos, Marie-Eve Carrier, Brooke Levis, Warren R Nielson, Susan J Bartlett, Laura Dyas, Lydia Tao, Claire Fedoruk and 32 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04246528 (The Scleroderma Patient-centered Intervention Network), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04246528 nacompletednot on this map

The Scleroderma Patient-centered Intervention Network (SPIN) Self-Management Program: Protocol for a Randomised Controlled Feasibility Trial With Progression to Full-Scale Trial

TypeinterventionalSponsorLady Davis InstituteRan2021 to 2025Enrolled169ConditionsScleroderma, Systemic SclerosisArmsSPIN-SELF Program
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Measurement equivalence of the English and French versions of the self-efficacy to manage chronic disease scale: a Scleroderma Patient-Centered Intervention Network (SPIN) study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors at 20 institutions in 7 countries.

Julia Nordlund *Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
Richard S Henry *Lady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
Linda KwakkenbosDepartment of Clinical Psychology, Radboud University, Nijmegen, The Netherlands.
Marie-Eve CarrierLady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
Brooke LevisCentre for Prognosis Research, School of Medicine, Keele University, Keele, Staffordshire, UK.
Warren R NielsonSt. Joseph's Health Care, London, Ontario, Canada.
Susan J BartlettDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Laura DyasScleroderma Foundation, Michigan Chapter, Southfield, MI, USA.
Lydia TaoLady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
Claire FedorukLady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
Karen NielsenScleroderma Society of Ontario, Hamilton, Ontario, Canada.
Marie HudsonLady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
Janet PopeDepartment of Medicine, University of Western Ontario, London, Ontario, Canada.
Tracy FrechDepartment of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Shadi GholizadehCalifornia School of Professional Psychology/Alliant, Los Angeles, CA, USA.
Sindhu R JohnsonToronto Scleroderma Program, Mount Sinai Hospital & Toronto Western Hospital, Toronto, Ontario, Canada.
Pamela PiotrowskiPrivate practice - Nutrition, Milton, Ontario, Canada.
Lisa R JewettDepartment of Psychology, Jewish General Hospital, Montreal, Quebec, Canada.
Jessica GordonDepartment of Medicine, Hospital for Special Surgery, New York City, NY, USA.
Lorinda ChungDepartment of Medicine, Stanford University, Palo Alto, CA, USA.
Dan BilskerFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Alexander W LevisDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Kimberly A TurnerLady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
Julie CuminLady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada.
Joep WellingNVLE Dutch patient organization for systemic autoimmune diseases, Utrecht, The Netherlands.
Catherine FortunéOttawa Scleroderma Support Group, Ottawa, Ontario, Canada.
Catarina LeiteUniversity of Minho, Braga, Portugal.
Karen GottesmanScleroderma Foundation, Los Angeles, CA, USA.
Maureen SauveScleroderma Society of Ontario, Hamilton, Ontario, Canada.
Tatiana Sofía Rodríguez-ReynaInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Maggie LarcheDepartment of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
Ward van BredaFaculty of Behavioural and Movement Sciences, VU University, Amsterdam, The Netherlands.
Maria E Suarez-AlmazorDepartment of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Amanda WurzSchool of Kinesiology, University of the Fraser Valley, Chilliwack, British Columbia, Canada.
Nicole Culos-ReedFaculty of Kinesiology, University of Calgary, Calgary, Alberta, Canada.
Vanessa L MalcarneDepartment of Psychology, San Diego State University, San Diego, CA, USA.
Maureen D MayesDepartment of Internal Medicine, University of Texas McGovern School of Medicine, Houston, TX, USA.
Isabelle BoutronUniversité de Paris, Centre of Research Epidemiology and Statistics (CRESS), Inserm, INRA, Paris, France.
Luc MouthonService de Médecine Interne, Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Andrea BenedettiDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
Brett D ThombsLady Davis Institute of the Jewish General Hospital, 3755 Côte-Sainte-Catherine Road, Montreal, Quebec, H3T 1E2, Canada. brett.thombs@mcgill.ca.ORCID http://orcid.org/0000-0002-5644-8432
SPIN Investigators
Jewish General Hospital · CAMcGill University Health Centre · CAThe University of Texas MD Anderson Cancer Center · USInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXMcGill University · CAMultiple Sclerosis Society of Canada · CAScleroderma Foundation · USAlberta Health Services · CAAlliant International University · USCentre Hospitalier Universitaire de Lille · FRHarvard University · USHospital for Special Surgery · USImpact · CAInserm · FRKeele University · GBMilton District Hospital · CAMount Sinai Hospital · CARadboud University Nijmegen · NLSan Diego State University · USSt Joseph's Health Care · CA

Funding

CIHR 201603PJT
6 · The paper itself

Abstract

backgroundSystemic sclerosis (scleroderma; SSc) is a rare autoimmune connective tissue disease. We completed an initial feasibility trial of an online self-administered version of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program using the cohort multiple randomized controlled trial (RCT) design. Due to low intervention offer uptake, we will conduct a new feasibility trial with progression to full-scale trial, using a two-arm parallel, partially nested RCT design. The SPIN-SELF Program has also been revised to include facilitator-led videoconference group sessions in addition to online material. We will test the group-based intervention delivery format, then evaluate the effect of the SPIN-SELF Program on disease management self-efficacy (primary) and patient activation, social appearance anxiety, and functional health outcomes (secondary).

methodsThis study is a feasibility trial with progression to full-scale RCT, pending meeting pre-defined criteria, of the SPIN-SELF Program. Participants will be recruited from the ongoing SPIN Cohort ( http://www.spinsclero.com/en/cohort ) and via social media and partner patient organizations. Eligible participants must have SSc and low to moderate disease management self-efficacy (Self-Efficacy for Managing Chronic Disease (SEMCD) Scale score ≤ 7.0). Participants will be randomized (1:1 allocation) to the group-based SPIN-SELF Program or usual care for 3 months. The primary outcome in the full-scale trial will be disease management self-efficacy based on SEMCD Scale scores at 3 months post-randomization. Secondary outcomes include SEMCD scores 6 months post-randomization plus patient activation, social appearance anxiety, and functional health outcomes at 3 and 6 months post-randomization. We will include 40 participants to assess feasibility. At the end of the feasibility portion, stoppage criteria will be used to determine if the trial procedures or SPIN-SELF Program need important modifications, thereby requiring a re-set for the full-scale trial. Otherwise, the full-scale RCT will proceed, and outcome data from the feasibility portion will be utilized in the full-scale trial. In the full-scale RCT, 524 participants will be recruited. DISCUSSION: The SPIN-SELF Program may improve disease management self-efficacy, patient activation, social appearance anxiety, and functional health outcomes in people with SSc. SPIN works with partner patient organizations around the world to disseminate its programs free-of-charge.

trial registrationClinicalTrials.gov NCT04246528 . Registered on 27 January 2020.

Indexed as

COVID-19Scleroderma, SystemicSelf-ManagementFeasibility StudiesHumansPatient-Centered CareRandomized Controlled Trials as Topice-HealthPatient activationRandomized controlled trialSclerodermaSelf-efficacySelf-managementSystemic sclerosis

Identifiers

PMID34838105
PMCPMC8626736
OpenAlexW3214930221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.